Overview

Anlotinib in Advanced Solid Tumors With FGFR Alteration

Status:
Recruiting

Trial end date:
2023-07-01

Target enrollment:
0

Participant gender:
All

Summary

This clinical trial aims to evaluate the efficacy, safety of Anlotinib in advanced solid tumors with FGFR alteration.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Shanghai Changzheng Hospital

Criteria

Inclusion Criteria:

Patients should be histologically diagnosed with advanced solid tumors; Patients with FGFR
mutation(including mutation, fusion, rearrangements ); Patients have measurable lesions;
Patients are not available for targeted therapy or patients refuse to receive targeted
therapy afer second-line treatment; Over 3 weeks after radiotherapy and the radiotherapy
focus was not be measured; Age should be 18-25 years; Performance status should be 0-2;
Life expectancy should be more than 12 weeks;

Exclusion Criteria:

Patients underwented major surgery or severe trauma within 4 weeks; Patients allergiced to
experimental drugs; Patient ready to give birth or who is pregnant; Patients with brain
metastases; Patients with chemotherapy contraindication; Patients could not tolerate
chemotherapy; Patients have secondary primary tumor.